Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review

June 2021 | 50 pages | ID: CEAD77B7B73EN
GlobalData

Abstracts

Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform that develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.

Cellectar Biosciences Inc Key Recent Developments

Jun 24,2021: Cellectar announces the election of Dr. Asher Alban Chanan-Khan to its Board of Directors
May 10,2021: Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
Mar 05,2021: Cellectar to Participate at Upcoming Institutional Investor Conferences
Mar 02,2021: Cellectar reports financial results for year ended December 31, 2020 and provides a corporate update
Feb 10,2021: Cellectar to Present at BIO CEO & Investor Digital Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Cellectar Biosciences Inc - Key Facts
Cellectar Biosciences Inc - Key Employees
Cellectar Biosciences Inc - Key Employee Biographies
Cellectar Biosciences Inc - Major Products and Services
Cellectar Biosciences Inc - History
Cellectar Biosciences Inc - Company Statement
Cellectar Biosciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cellectar Biosciences Inc - Business Description
Cellectar Biosciences Inc - SWOT Analysis
SWOT Analysis - Overview
Cellectar Biosciences Inc - Strengths
Cellectar Biosciences Inc - Weaknesses
Cellectar Biosciences Inc - Opportunities
Cellectar Biosciences Inc - Threats
Cellectar Biosciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cellectar Biosciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 24, 2021: Cellectar announces the election of Dr. Asher Alban Chanan-Khan to its Board of Directors
May 10, 2021: Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
Mar 05, 2021: Cellectar to Participate at Upcoming Institutional Investor Conferences
Mar 02, 2021: Cellectar reports financial results for year ended December 31, 2020 and provides a corporate update
Feb 10, 2021: Cellectar to Present at BIO CEO & Investor Digital Conference
Nov 09, 2020: Cellectar reports third quarter 2020 financial results and provides a corporate update
Aug 10, 2020: Cellectar reports second quarter 2020 financial results and provides a corporate update
Jul 01, 2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
Jun 01, 2020: Cellectar granted SME status by the European Medicines Agency
May 07, 2020: Cellectar reports first quarter 2020 financial results and provides a corporate update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Cellectar Biosciences Inc, Key Facts
Cellectar Biosciences Inc, Key Employees
Cellectar Biosciences Inc, Key Employee Biographies
Cellectar Biosciences Inc, Major Products and Services
Cellectar Biosciences Inc, History
Cellectar Biosciences Inc, Subsidiaries
Cellectar Biosciences Inc, Key Competitors
Cellectar Biosciences Inc, Ratios based on current share price
Cellectar Biosciences Inc, Annual Ratios
Cellectar Biosciences Inc, Annual Ratios (Cont...1)
Cellectar Biosciences Inc, Interim Ratios
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cellectar Biosciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Cellectar Biosciences Inc, Performance Chart (2016 - 2020)
Cellectar Biosciences Inc, Ratio Charts
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021